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Abstract
Purpose: Autosomal recessive conditions, while individually rare, are a significant 
health burden with limited treatment options. Population carrier screening has been 
suggested as a means of tackling them. Little is known, however, about the attitudes of 
the general public towards such carrier screening and still less about the views of peo-
ple living with candidate genetic diseases. Here, we focus on the role that such experi-
ence has on screening attitudes by comparing views towards screening of people with 
and without prior experience of the monogenetic disorder, Spinal Muscular Atrophy.
Methods: An exploratory sequential mixed methods design was adopted. In- depth 
qualitative interviews were used to develop two surveys. The surveys addressed atti-
tudes towards carrier screening (pre- conceptual and prenatal) for SMA.
Participants: 337 participants with SMA experience completed the SMA Screening 
Survey (UK) and 336 participants with no prior experience of SMA completed the UK 
GenPop Survey, an amended version of the SMA Screening Survey (UK).
Results: The majority of both cohorts were in favour of pre- conception and prenatal 
carrier screening, however people with experience of type II SMA were least likely to 
support either. Key differences emerged around perceptions of SMA, with those with-
out SMA experience taking a dimmer view of the condition than those with.
Conclusion: This study underscores the significance of prior experience with the con-
dition to screening attitudes. It highlights the need for accurate and high- quality edu-
cational resources to support any future carrier screening programmes, that particularly 
in relation to rare genetic disorders like SMA that will fall outside the remit of everyday 
experience for the majority of the population.
K E Y W O R D S
ethics, experiential knowledge, genetic screening, spinal muscular atrophy
1  | INTRODUCTION
As reproductive genetic medicine advances and the number of con-
ditions that can be detected through the use of genetic technologies 
increases, important questions need to be addressed about which 
conditions are suitable candidates for expanded genetic screening. 
While currently in the UK, NHS genetic testing is typically reserved 
for families with a known history of (or identified risk factors for) the 
particular genetic disorder in question, the development of technolo-
gies such as whole genome sequencing (WGS) are beginning to alter 
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the landscape and remit of genetic screening practices. Indeed, WGS 
allows for large panels (50+ conditions) of genetic conditions to be 
screened for simultaneously,1 making screening on a mass scale more 
technologically, practically and financially feasible than ever before. 
Furthermore, WGS is already expanding in its role within mainstream 
NHS health care, particularly in the areas of diagnostics and reproduc-
tion2,3 bringing to the fore questions of whether and how such large 
volume screens could (or indeed should) be offered to the general pop-
ulation with no known risk factors for genetic disease.4
One of the key arguments in favour of the expansion of genetic car-
rier screening, particularly pre- conception genetic screening (PCGS), 
concerns its capacity to extend and enhance the reproductive options 
of would- be parents who are carriers of genetic disorders.5 Currently, 
such parents most commonly learn of their genetic carrier status after 
the birth of an affected child. PCGS, however, by alerting prospective 
parents to their carrier status before a pregnancy is even conceived, 
increases the reproductive options of such couples by permitting them 
access to reproductive technologies (eg pre- implantation genetic diag-
nosis, the use of donated gametes) for use in their first, rather than sub-
sequent, pregnancies. Prenatal genetic screening (PNGS) on the other 
hand, through carrier screening of pregnant women, their partners 
and/or foetuses would give expectant carrier parents the (otherwise 
inaccessible) option of preventing the birth of an affected foetus alto-
gether (through selective pregnancy termination), or provide them with 
the information required to prepare for the significant life changes that 
typically accompany the birth of a child with a serious genetic disorder.
In spite of the potential for increased reproductive autonomy af-
forded by the use of genetic screening, as outlined above, however, its 
expansion would also represent a significant shift in the nature and type 
of reprogenetic decisions facing would- be parents. Carrier screening 
would demand that such parents make life-altering reproductive deci-
sions based on the abstract notion of their genetic carrier status rather 
than the more tangible experience of genetic disease in their family.6 
Indeed, they may be required to make screening decisions in relation 
to conditions they are likely to have never come across, or even heard 
of before. As such, reproductive decision- making appears set to be in-
creasingly dislocated from the experiential reality of genetic disease.
While various studies have been carried out to gauge public atti-
tudes towards the expansion of genetic carrier screening,1 far fewer 
have considered the views of families currently living with genetic 
diseases.7,8 Such families can be described as possessing direct “ex-
periential knowledge” of the condition in question.9 This experiential 
knowledge has variously been described as “embodied” (ie having 
the condition oneself), or “empathetic” (ie experiencing the condition 
through close proximity to a person with it). Both of these forms of 
knowledge have been demonstrated to play a key role in shaping and 
informing the reproductive attitudes and decisions of families living 
with genetic diseases in various different ways.7,8,10-12 Members of 
the general public, however, approach screening decisions from an 
entirely different vantage point comparatively to make the very same 
decisions which, up until now, were only made experienced affected 
families face: whether or not to use genetic technologies to prevent or 
avoid the birth of a child with that condition.13
In spite of this emerging body of literature, however, research-
ers exploring the acceptability, or potential impact, of genetic carrier 
screening have tended to focus their attention exclusively on either the 
reproductive attitudes of the general public1,14,15 (the targets of carrier 
screening) or (less often) the views of affected families.16 However, 
there remains very little cross- referencing of this literature.17 This is in 
spite of the fact that such a comparison brings sharply into focus the 
disparity of knowledge, experience and information between affected 
families, and the people who (through carrier screening) will become 
the new generation reprogenetic decision- makers in relation to that 
condition, the general public. Here, we report on such a comparison, 
to highlight the broader social and ethical concerns around expanded 
carrier screening, using Spinal Muscular Atrophy (SMA) as an example.
1.1 | Spinal muscular atrophy
Spinal muscular atrophy (SMA) is the most common genetic cause 
of infant death worldwide and yet is generally considered to be a 
relatively obscure condition.18 It is an autosomal recessive disorder 
caused by deletions of the Survival Motor Neuron (SMN) gene.19,20 
SMN deletions trigger in the apoptotic loss of the alpha motor neu-
rones of the spinal cord, result in progressive and symmetrical atrophy 
of the voluntary muscles of the limbs and trunk.
Spinal muscular atrophy includes clinical categories that are based 
on the severity of the disease and the age of onset.18 Type I SMA (se-
vere SMA) emerges within the first 4 months of life, with affected chil-
dren usually dying through respiratory failure within 2 years.18 Type 
II SMA (intermediate) is the most heterogeneous form, with onset 
usually within the first 2 years of life and most affected individuals 
living normal or near- normal lifespans.18 Type III SMA is usually di-
agnosed after the age of 4 years, with the majority of able to sit and 
stand unaided (although this may later be lost) and life span usually 
unaffected.18 Type IV SMA is the form of SMA with the latest onset 
(typically in the 2nd or 3rd decade of life). Lifespan is unaffected in type 
IV SMA, although, like type III, adults with this form of SMA experi-
ence increasing level muscle weakness over time and most eventually 
lose the ability to walk unaided.
While the typing system for SMA has long been used as a short-
hand for disease severity both within and without the medical profes-
sion, it is also acknowledged that this way of categorizing SMA results 
in types with a high degree of overlap between them and broad ranges 
of disease severity within them.21
1.2 | Spinal muscular atrophy and genetic screening
As SMA is an autosomal recessive condition (a single gene disorder 
requiring two carrier parents to transmit), this means that each preg-
nancy conceived by carrier parents has a 1 in 4 chance of having SMA. 
Estimates of carrier frequency in the general population vary con-
siderably, although generally fall within the region of 1:40 and 1:60. 
The condition is estimated to affect 1 in every 6000- 10 000 births 
worldwide.22 While prenatal testing and/or cascade carrier screen-
ing is routinely offered to families with a known history of SMA, 
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screening of the general population is somewhat more controver-
sial.8,23,24 Indeed, there is a distinct lack of consensus amongst leading 
authorities on whether screening is advisable.25,26 Key concerns that 
have prevented a screening programme for SMA being introduced in 
the UK context include a lack of effective treatments, an accepted 
requirement for newborn screening25 (although the recent FDA ap-
proval of Nusinersen,27 a drug which has been demonstrated to im-
prove the muscle function of some children with SMA, may lead to 
increased pressure to revise this policy), and the inability of screen-
ing tests to accurately distinguish disease severity.25 Data presented 
here is aimed at addressing whether this second concern is seen as a 
significant issue in both affected families and the general population.
Using the SMA Screening Survey (UK), we have previously reported 
that within a sample of 337 affected family members and adults with 
SMA, there was relatively widespread support for both PCGS and 
PNGS, although adults and families affected by type II SMA expressed 
the most resistance.8 Here, we compare and contrast the reproductive 
views and attitudes of these affected families to those of people in the 
general population. The presented data allows a thorough and detailed 
investigation of the current views on SMA screening in the UK and 
allows interesting insightful comparisons between different subpopu-
lations of people set to be directly affected (albeit in contrasting ways) 
if screening for SMA were to be introduced. The general relevance to 
other potential screening programmes in the UK will also be discussed.
2  | METHODS
An exploratory sequential mixed methods research design was 
adopted for this study. This design was chosen as it allows for both 
an in- depth exploration of the complex and sensitive topic of screen-
ing, while also permitting the breadth and generalizability of analy-
sis most commonly associated with quantitative approaches. The 
research took place in three distinct phases, involving qualitative in-
terviews (phase I) and two surveys (phase II), before a merged quan-
titative analysis (phase III). This paper focuses on phases II and III of 
the study, with phase I qualitative data presented elsewhere.7,8 The 
project was supported and guided by three expert panels of profes-
sionals involved with, and people living with, SMA. Ethical approval 
for the study was granted by the University of Warwick’s Biomedical 
and Scientific Research Ethics Committee in July 2014.
2.1 | Qualitative interviews: Phase I
To gain a deeper understanding of the nature of attitudes towards 
screening for SMA amongst affected families, in- depth qualitative 
interviews were conducted with 36 people who either have SMA 
themselves, or have SMA in their family, recruited through the main 
support and advocacy group for people living with SMA in the UK, 
SMA Support UK. The interviews were designed to explore partici-
pants’ experiences with SMA, their views around, and experiences of, 
genetic testing technologies and selective termination, as well as their 
perceptions of PCGS/PNGS for SMA.
2.2 | The SMA screening survey (UK): Phase II
Details of the development SMA Screening Survey (UK) have been 
presented in greater detail elsewhere.8 In brief, the survey was 
directly informed by phase I qualitative data. As the aim of this re-
search programme was to explore the nature and spread of attitudes 
amongst families living with SMA key themes from phase I were ini-
tially used to delineate the key domains of the survey. These broad 
domains were then later transformed into single sentence “attitude/
belief” statements, and subsequently developed into quantitative sur-
vey questions through the use of a Lickert scale. Using this approach, 
respondents were able to state their degree of agreement/disagree-
ment with them. Where possible, the actual words of participants who 
articulately encapsulated a particular theme within their interview 
were used directly as an attitude statement.
Given that participants in the SMA Screening Survey (UK) were 
already aware of their genetic risk status (or the possibility of it) and 
therefore would not be the intended recipients of population- level 
PCGS or PNGS, the survey was designed to capture their attitudes to-
wards, rather than intended use of, these screening programmes. This 
was measured by the degree to which participants stated that they 
would support a PCGS or PNGS programme. Further questions were 
then developed to explore key reasons for support and non- support.
2.3 | UK GenPop survey: Phase III
To compare the views of families living with SMA towards PCGS/
PNGS screening with the views of people with no prior experience of 
SMA, the SMA Screening Survey (UK) questions on PCGS/PNGS were 
replicated to produce a shorter more focused survey (the UK GenPop 
Survey). Key questions were replicated to allow direct comparison of 
the data generated from both surveys. As the UK general population 
are understood to have poor knowledge of SMA,28 information was 
included within the UK GenPop Survey to explain what SMA is and 
how it affects people in its various forms. This information was repli-
cated with permission from SMA Support UK’s resources and as such 
is certified by the UK Information Standard.
To access people with no prior experience of SMA, The UK GenPop 
Survey was distributed digitally through the School of Life Sciences 
(University of Warwick), including students and staff. Participants were 
then asked to circulate the survey through social media (Facebook). 
Unlike the SMA Screening Survey (UK), the UK GenPop Survey was 
only available in online format. To reduce the impact of selection bias 
and over- representation of students, participants <25 years of age 
were excluded from the analysis.
2.4 | ill-equipped User involvement
As well as the underpinning qualitative work, the three phases of the 
research were also supported by expert review panels. The first of 
these panels comprised of six staff members from SMA Support UK. 
The second group consisted of four members of SMA Patient Registry 
staff. These two professional panels reviewed the SMA Screening 
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Survey (UK) once it had been completed in its draft form, offering 
feedback on the questions as well as advice on the implementation 
strategy. A separate expert review panel, made up of people living 
with SMA (nine people who had SMA themselves and six who had 
a relative with SMA), met to discuss the phase I qualitative analysis, 
the early design of the survey as well as to offer feedback on the first 
completed draft of the SMA Screening Survey (UK). A final meeting of 
this panel was held upon completion of the quantitative survey analy-
sis to discuss dissemination and the wider implications of the findings.
2.5 | Data stratification and statistical analysis
Responses to each question were stratified as follows: gender (Male 1 
v Female 0); age (35- 45 1 v other 0); qualifications (degree or above (1) 
v other (0)); religious (yes (1) v no (0)); do you have children (yes (1) v no 
(0)); relationship to SMA (patient (1) v family (0)); type of SMA associ-
ated with your family (type 0 or type 1(1) v other (0)); living or lived with 
an SMA patient (yes (1) v no (0)); current health (good or very good (1) 
v other (0)); current pregnant or trying to get pregnant (yes (1) v no (0)). 
For all questions regarding screening answers were stratified as either 
agree/strongly agree (1) or other (0). This was done because it allowed 
the simplest way of assessing the positive views of respondents.
The attitudes of the general population towards PCGS/PNGS SMA 
screening were compared to responses from responses from the SMA- 
associated population (n=337) to identify major differences. These were 
then further investigated by comparing the general population with: 1) 
adults with SMA (types II and III); and 2) family members associated 
with SMA (types I, II and III) to determine if there were any statistical 
differences (N.B. due to the poor prognosis associated with SMA type 
I, no adults with this diagnosis were included in the study). For each 
question the number of “agree” vs “other” responses were reported and 
statistical differences between the subgroups were assessed using a 
chi- squared analysis (GraphPad Prism software, v6). It is important to 
note that for the subanalysis, the SMA- associated sample was reduced 
to 287 participants through the removal of people associated with vari-
ant types of SMA (type IV SMA, Spinal Bulbar Muscular Atrophy and 
Spinal Muscular Atrophy with Respiratory Distress). This was done to 
enable a more meaningful comparison with the general population data.
3  | RESULTS
3.1 | Non- SMA v SMA populations: Comparative 
cohort descriptive characteristics
In total, there were 336 responses from the general population and 337 
from SMA- associated families (255 family members (75.7%) and 82 
(24.3%) with SMA themselves). Basic descriptive analysis of the gen-
eral population data revealed that 146 (43%) were female; 187 (56%) 
were educated to degree level or higher and 208 (62%) were religious 
(Table 1). When these values were compared to the demographics of 
SMA- associated participants, there were significant differences in the 
gender, with a higher proportion (75%) of the SMA- associated partici-
pants being female (P<.0001) and less highly educated, with 64% of 
the cohort not educated to degree level (P<.0001) (Table 1). Levels of 
religiosity, however, appeared similar between the two groups (P=.96; 
Table 1).
3.2 | Non- SMA v SMA populations: Comparisons of 
views on pre- conception genetic screening (PCGS)
A direct comparisons on the two studied populations (non- SMA and 
SMA) shows a significant difference in the levels of support for PCGS 
(86% v 77%, respectively; P=.004) (Table 2). This difference is predom-
inantly driven by participants associated with type II SMA. Indeed, the 
levels of support in the general population (86%) were similar to the 
support expressed by people associated with type I (family members 
88%, P=.47) and type III (Family members 73%, P=.09; adults with 
SMA 94%, P=.22). However, significantly less support was observed 
in both family members associated with type II SMA (72%, P=.003) 
and adults with type II SMA (63%, P=.001) (Table 1).
3.3 | SMA subtypes v general population: 
Reasons for and against support of pre- conception 
genetic screening
Assessment of the PCGS subquestions indicate that the majority of 
the general population thought PCGS was beneficial because they 
TABLE  1 Characteristics and demographics of survey responders. 
Demographics are shown for responders from the general population 
(n=336), responders associated with SMA families (n=337). Response 
distributions were compared between the two groups and significant 
differences were assessed using chi- squared analysis (P- value)
Characteristic
General 
population 
(n=336)
SMA screening 
survey (n=337) P- Valuea
Gender - no. (%) <.0001
Male 190 (57%) 85 (25%)
Female 146 (43%) 251 (75%)
Age <.0001
18- 25 y Excludedb 16 (5%)
26- 34 y 79 (24%) 40 (12%)
35- 45 y 80 (24%) 99 (29%)
46- 55 y 108 (32%) 76 (23%)
56- 65 y 44 (13%) 49 (15%)
>65 y 25 (7%) 56 (17%)
Qualifications <.0001
Degree or 
higher
187 (56%) 122 (36%)
Other/none 149 (44%) 215 (64%)
Religious .96
Yes 208 (62%) 185 (55%)
No 128 (38%) 113 (45%)
aP values were calculated with the use of the chi- squared test.
b18- to 25- y- olds were excluded to reduce selection bias (see Section 2).
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believed it would reduce the number of SMA- associated terminations 
(80%; Table 2). In comparison, a much lower percentage of family 
members and adults with type II SMA thought PCGS would reduce the 
number of terminations (GP 80% v families 68%, P=.01; v adults with 
type II 56%, P=.003; Table 2). The majority of participants from the 
general population also thought that PCGS would raise awareness of 
SMA in the general population (GP 90%). This belief was also reflected 
in the responses of SMA- associated participants (88%; Table 2) with 
the exception of those participants associated with type II SMA (type 
II family members 80%, P=.009; adults with type II 74%, P=.008) 
(Table 2). Moreover, adults with type II SMA were significantly more 
likely than any other group included in this analysis to believe that 
PCGS is a form of social engineering (GP 18% v adults with type II 
56%, P<.0001; Table 2).
While overall, type I associated participants were the group most 
similar to the general population than any other SMA- associated par-
ticipants, differences between these two groups also emerged: more 
participants in the general population thought that PCGS would lead 
to carrier stigmatization (GP 28% v adults with type II 8%, P<.0001; 
Table 2) and more type I family members thought it would raise SMA 
awareness (type I family members 90% v GP 96%, P=.06; Table 2).
Only one significant difference was identified between the general 
population and type III participants, with fewer participants from the 
general population agreeing that carrier identification would change 
their choice of reproductive partners (GP 35% v type III families 59%, 
P=.02; v adults with type III 52%, P=.003; Table 2).
3.4 | Non- SMA v SMA populations: Comparison of 
views on prenatal genetic screening (PNGS)
Overall, 84% of non- SMA- associated participants surveyed were in 
favour of PNGS (Table 3). As with PCGS, this was significantly higher 
than amongst the SMA- associated population (76%; P=.009) (Table 3). 
Again, this difference was predominantly driven by participants as-
sociated with type II SMA (family members 72%, P=.005; adults with 
type II 52%, P=.002; Table 3).
3.5 | SMA subtypes v general population: Reasons 
for and against support of pre- conception genetic 
screening (PCGS)
The majority of the general population agreed that PNGS would 
allow everyone to make informed decisions (85%) and this belief 
was widely held by all analysed participants (Table 3). The general 
population generally agreed that PNGS would prevent suffering 
(66%). In comparison, however, significantly fewer type II associated 
participants agreed with this statement (GP, 66%; type II families 
52%, P=.01; adults with type II 22%, P<.0001) (Table 3). In contrast, 
significantly more type I families thought it would reduce suffering 
(79%, P=.007; Table 3). Non- SMA- associated participants generally 
agreed that a PNGS programme would raise awareness of SMA in 
the general population (87%) (Table 3). While most SMA- associated 
groups agreed with this, there was significantly less agreement 
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amongst adults with type II SMA (GP (87%) v type II adults (70%; 
P=.01; Table 3).
It is noteworthy that only 22% of participants from the general 
population thought that people diagnosed with SMA could live fulfill-
ing lives; this was significantly lower than all SMA- associated partici-
pants, even those associated with type I SMA, whose views elsewhere 
have been more closely aligned with the general population (Table 3). 
This finding was also underscored by the fact that only 10% of the 
general population agreed that a reduction in the number of SMA chil-
dren coming into the world would be a loss to society—this was signifi-
cantly lower than all SMA- associated subgroups with the exception of 
type III family members (14%; Table 3).
The possible inability of members of the public to refuse the screen 
emerged as a more significant concern to members of the general pop-
ulation than it was to all SMA- associated participants except for adults 
with type II SMA (type I family members 49% v 23%, P<.0001; type II 
family members 49% v 29%, P=.0006; type III family members 49% v 
18%, P=.004; adults with type III SMA 49% v 23%, P=.004) (Table 3). 
Indeed, this concern around ability to refuse screening was the only 
question for which the views of non- SMA- associated participants 
most closely aligned with those of adults with type II SMA.
While the views of type I families and the general population were 
relatively closely matched on questions regarding PCGS, areas of di-
vergence most clearly emerged within the PNGS subquestions. One 
of these concerned the ability of genetic technologies to provide in-
formation on type. Thus far, the lack of accurate information on dis-
ease severity that could be provided through PNGS for SMA has been 
regarded as a major stumbling block to its introduction. For families 
living with type I SMA, however, unlike the general population this was 
not considered a preclusion to its introduction, with significantly more 
agreeing that screening is still useful even with these limitations (type 
I family members 77% v GP 55%; P<.0001) (Table 3). Moreover, when 
compared to the general population, significantly more type I family 
members than any other SMA- associated group agreed that termina-
tion of foetuses with milder forms of SMA is an unfortunate (but nec-
essary) by- product if we are to ensure that children with severe SMA 
are not born (type I families 40% v GP 29%, P=.02) (Table 3). In con-
trast, the group expressing the strongest opposition to this notion was 
adults with type II SMA (type II adults 29% v GP 11%, P=.04) (Table 3), 
with over double the number of members of the general public agree-
ing with the statement than type II adults.
4  | DISCUSSION
This paper presents the first extended comparison of the views of the 
general population and families associated with SMA on potential PCGS 
and PNGS programmes in the UK. The data presented here reveal that 
both groups are generally in favour of both screening programmes, 
although PCGS elicited slightly more supported than PNGS. This is in 
keeping with previous reports28,29 and reflects a widespread belief in 
the importance of earlier screens and the prevention of SMA without 
the need for selective pregnancy termination. Overall, however, the 
population without prior experience of SMA was more supportive of 
both types of screening than SMA- associated participants.
The major area of divergence between the two studied popula-
tions appeared to centre around the way life with SMA was valued. 
Indeed, the general population viewed SMA significantly more neg-
atively than SMA- associated families, the only exception being type 
I families, whose views were more closely aligned to those of the 
general population. This correlation suggests that when considering 
screening decisions, and in light of the inability of genetic technologies 
to accurately discern SMA type that people lacking prior knowledge 
of SMA may imagine screening decisions in terms of the “worst case 
scenario” and wish to guard against such an eventuality. In contrast, 
people with experience of SMA appeared to imagine future children 
with SMA within the framework of their existing experiential knowl-
edge; it was challenging for them to imagine such future lives as in-
volving anything other than a repetition of that with which they were 
familiar.30 This is in spite of the fact that it is possible for children with 
different types of SMA to be born to the same carrier parents. This 
finding highlights that it is not only possession of experiential knowl-
edge, but also the nature of that experiential knowledge that is critical 
in the formulation of screening attitudes.
The significance of the nature of SMA experience also appeared in 
the subanalysis of type II adults and families. Participants associated with 
this type of SMA were more likely than any other group to reject carrier 
screening programmes and to view the associated decline in numbers 
of people with SMA in the world as a loss to society. That adults with 
type II SMA are a group distinct from other adults diagnosed with SMA 
is an observation noted elsewhere in the literature.31,32 Kruitwagen- Van 
Reenen et al.,32 for example, argue that adults with type II SMA, despite 
their more severe clinical presentation than adults with type III, were 
more likely to rate their quality of life as high. We have argued else-
where that this finding also emerged within our own dataset and have 
argued that this may be due to the relatively fixed and congenital na-
ture of type II impairment8 when compared to the degenerative effects 
associated with both types I and III. Adults with type II, having always 
had their disability, are often well adjusted to it and develop their plans 
for their lives around its existence. Adults with types III SMA, however, 
while experiencing clinically milder symptoms, often go through periods 
of decline or deterioration in abilities and many eventually come to rely 
on a wheelchair. These contrasting experiences of SMA were inextrica-
bly bound up with the way in which adults with SMA related to and per-
ceived their condition, as well as its ramifications in terms of personal 
identity.8 Adults with type II SMA more frequently spoke of their con-
dition being an integral (and highly valued) part of their sense of self, a 
finding not nearly as prevalent amongst adults with milder disease. This 
finding is also reflected within disability studies as well as within the 
rehabilitation literature exploring attitudes to cure,33,34 whereby con-
trasting perspectives are observed between people who have relatively 
static congenital impairments (eg deafness), and those who acquire their 
impairment suddenly and unexpectedly (eg spinal cord injury), or who 
experience decline over time (eg Motor Neurone Disease).
While the nature (in terms of disease severity) of a person’s ex-
periential knowledge of SMA (or lack of) was found to be critical to 
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the formulation of screening perspectives, it is also noteworthy that 
whether or not the SMA- associated participant had SMA themselves 
(or were a family member of someone with SMA), did not significantly 
impact on reproductive attitudes. It has been argued that people with 
genetic diseases are the “best experts” on their own condition—that 
having the condition oneself affords that person a privileged vantage 
point from which to imagine the implications of having a child with that 
same condition.35,36 Our present analysis, however, highlights that “em-
pathetic” forms of experiential knowledge (ie knowing SMA through the 
experiences of a family member) could be just as influential in determin-
ing attitudes towards screening as embodied forms (having the condi-
tion oneself).8 The centrality of empathetic knowledge to reproductive 
attitudes and decisions has been highlighted elsewhere.10,37,38 This 
present study suggests that it may be equally as important to incorpo-
rate the views of people with empathetic forms of experiential knowl-
edge when exploring the reproductive attitudes of people affected by 
genetic diseases. Indeed, despite not having the condition themselves, 
the viewpoints of family members were shown by this study to be more 
similar to those of adults with SMA (with the same type) than they were 
to the general population, highlighting the pervasiveness of both em-
bodied and empathetic experience in altering attitudes.
Further research is indicated to explore perceptions of disease se-
verity in the context of genetic screening programmes across a wider 
spectrum of genetic diseases and incorporating different symptoms 
not typically associated with SMA (eg cognitive impairment, pain). As 
this study highlights, the correlation between disease severity and 
support for genetic screening programmes was not straightforward; 
screening support could not be accurately predicted based on the 
severity of SMA a person had experience of. This dislocation of the 
condition’s (clinical) severity from the various ways it came to be ex-
perienced and valued in both the contexts of everyday life, but also in 
the arena of reproduction, warrants further and serious consideration. 
As the capacities of reprogenetic technologies continue to expand and 
increasing numbers of conditions fall within its remit, policy decisions 
need to be made concerning which conditions should be included on 
genetic screening panels (and offered to the general public) and which 
should not. While the clinical severity of the disease may be amongst 
the most important considerations for such decisions (particulary in 
the context of a publicly funded health- care system), this study high-
lights the critical dissonance between the clinical presentation of a 
condition, and a person’s lived experience of it.
5  | CONCLUSIONS
Overall, this study highlights that while support for PNGS and PCGS 
was high amongst both SMA- associated participants and the general 
population, that clear differences nevertheless emerged between 
the two populations, with the general public generally taking a far 
more negative view of SMA than the families who live with it. This 
was with the exception of type I families, whose responses more 
closely mirrored those of the general population than other SMA- 
associated participants. In so doing, this study highlights the centrality 
of experiential knowledge in determining reprogenetic attitudes, and 
consequently its significance to future genetic screening programmes, 
both in terms of policy debates, but also in terms of information provi-
sion, for prospective parents facing increasingly abstract- and increas-
ingly complex- reproductive decisions.
5.1 | Limitations
Due to confidentiality and data protection issues, no identifiable data 
were asked of individuals who participated in the SMA Screening 
Survey (UK) or the UK GenPop Survey, including IP addresses (where 
the survey was completed online). This meant that there was no mech-
anism in place to prevent an individual completing multiple surveys. 
Due to the poor prognosis associated with type I SMA, all of the adults 
with SMA who participated in this study were diagnosed with clini-
cally less severe forms of SMA (types II and III). While this may have 
influenced the way in which SMA was perceived, we feel this limitation 
was minimized by the inclusion of type I associated family members. 
Furthermore, all forms of SMA can be associated with significant dis-
ability. Participants who completed the UK Genpop Survey were re-
cruited through the University of Warwick’s School of Life Sciences and 
through social media (Facebook links to the survey). It is possible that 
this recruitment strategy introduced bias in the sample. Efforts were 
made to circumvent this limitation, however, by excluding all Genpop 
participants under the age of 25 from the analysis (130 in total).
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